Jim was diagnosed with glioblastoma—one of the deadliest brain cancers. Facing dismal survival rates and a standard of care that hasn’t changed in over 20 years, he joined an @In8bio trial using his immune system to fight back. Jim's alive today—he is defying the odds. Watch

This Glioblastoma Awareness Day, we honor and recognize all those battling this terrible disease. You are not alone. We see you and are fighting for you! At IN8bio, we are working to advance new treatment options for patients with glioblastoma. We believe that change is

Our CEO, William Ho, had the pleasure of speaking with the Progress, Potential, And Possibilities Podcast about IN8bio, our DeltEx platform and how we are transforming patient care. Check out the full interview! https://t.co/mcjhgOhdgj @ProgressPotent1 @irat1onal #IN8bio $INAB

Happy #IndependenceDay from all of us at IN8bio!

We celebrate the significance of Juneteenth by honoring the resilience and struggles of those who came before us.  #Juneteenth2025

We are happy to announce that our COO, Kate Rochlin, PhD, will participate in a panel discussion, “Scalable Biomanufacturing for Living Medicines: Pioneering the Future Today,” tomorrow, June 17th, at the BIO International Convention in Boston, MA. We hope to see you there!

We are so excited to announce the achievement of our 4-year progression-free glioblastoma patient!  Thank you, @Nasdaq, for marking this momentous occasion for us at the Tower in Times Square.  The patient had a grade 4, IDH-mutant, MGMT-methylated glioma treated with the

IN8bio recognizes the achievement of an INB-200-treated patient who has reached 4 years in remission in the glioblastoma trial. This milestone is significant for the patient who presented with a grade 4, IDH-mutant, MGMT- methylated glioma and was treated with IN8bio’s

Dr. Burt Nabors, discusses @IN8bio’s gamma-delta T cell clinical trial results in GBM and what makes our approach different from others! Dr. Nabors is one of the nations leading neuro-oncologists and has been leading the frontlines in the battle against glioblastoma for 30

Jim was diagnosed with Glioblastoma… He was told he only had months to live, and now, 21 months later, he is still here and telling his story! His story is a powerful reminder of why we do what we do at IN8bio. Watch Jim’s GBM Story: https://t.co/hyPGnku3iu.

IN8bio’s DRI technology is designed to treat newly diagnosed GBM by harnessing the natural tumor-targeting power of gamma-delta T cells and the sensitizing effects of chemotherapy. This approach aims to eliminate residual GBM cancer cells that can persist and lead to relapse.

IN8bio is pleased to announce updated Phase 1 results of INB-200, IN8bio’s proprietary Drug Resistant Immunotherapy (DRI) gamma-delta T cells in newly diagnosed GBM.  GBM is a devastating disease, and we believe these promising results demonstrate the potential of gamma-delta T

We are live! REGISTER here: https://t.co/mFjrG5TeDn or access the listen-only version of the webcast here: https://t.co/dfOnb0qZ2q. $INAB

Exciting data from our Phase 1 INB-200 program presented in an oral session this weekend at ASCO2025! I heard great feedback from KOLs across the country as we try to make a real impact for these patients with GBM. Please join us on a conference call at 8:30am EDT as we review

$INAB to host conference call with principal investigator at 8:30am EDT today. REGISTER here: https://t.co/mFjrG5TeDn or access the listen-only version of the webcast here: https://t.co/dfOnb0qZ2q.

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival. Join us today, June 2nd at 8:30 am, for a company conference call to discuss the data with IN8bio management and Dr. Burt Nabors, the lead clinical

Jim was diagnosed with glioblastoma—one of the deadliest brain cancers. Facing dismal survival rates and a standard of care that hasn’t changed in over 20 years, he joined an @In8bio trial using his immune system to fight back. Jim's alive today—he is defying the odds. Watch

Did you know that the median survival for #GBM patients is only 12-18 months from diagnosis? At IN8bio, we believe that this is not enough. We believe that these patients deserve more than our sympathy—they demand our boldest ideas, our unwavering commitment and our attention.

Glioblastoma is a devastating brain cancer with a 5-year survival rate of less than 7%. Despite decades of research, treatment options are limited. We urgently need bold innovation, new therapies, and cutting-edge technologies like immunotherapy. IN8bio’s INB-200 therapy uses

Glioblastoma is the deadliest brain cancer and devastates patients, families, and the medical community, with burnout plaguing 61% of neuro-oncologists, 68% of allied health professionals, and 83% of scientists, based on recent Neuro-Oncology Practice findings. Yet, hope

At IN8bio, we believe innovation can’t wait. The INB-200 trial harnesses the power of our engineered gamma-delta T cell therapy to address one of the biggest challenges in oncology: Glioblastoma, a devastating cancer with a mere 12-month median survival rate. Despite being